In the inaugural event of the Global Cancer Movement, initiated by OncoDaily, Marwan Fakih explores groundbreaking research on identifying patients with microsatellite-stable (MSS) colorectal cancer (CRC) who may respond to immunotherapy, despite the absence of strong tissue biomarkers.
Key discussion points include:
- Clinical signatures that predict immunotherapy response in MSS-CRC.
- The role of PD-1 and CTLA-4 inhibition in improving treatment outcomes.
- The impact of metastatic sites, with liver metastases linked to resistance.
- Findings from key studies, including JAMA Network (2021) and LEAP-017 trials.
- The potential of CTLA-4 inhibitors in enhancing responses in non-liver metastases.